Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- ...

Author's Disclosures of Potential Conflicts of Interest End of Rituximab Maintenance for Low–Tumor Burden Follicular Lymphoma The following represents disclosure information provided by authors of ...

Strati led a study that evaluated acalabrutinib alone or in combination with rituximab for follicular lymphoma. In treatment-naive patients, the combination led to an ORR of 92% and CR rate of 39%.

Celgene Corporation (($CELG)) announced an update on their ongoing clinical study. Celgene Corporation recently completed a Phase 3B study titled ...

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma.

Patients had had relapse after or were refractory to three courses of conventional chemoimmunotherapy that included rituximab; after consolidation, they all received rituximab maintenance therapy.

The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free survival in combination therapy.

Among patients with relapsed or refractory follicular lymphoma (FL), the treatment combination of Monjuvi (tafasitamab-cxix) plus Revlimid (lenalidomide) and Rituxan (rituximab) has been found to ...

iv Rivas-Delgado A, Magnano L, Moreno-Velázquez M, et al. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era.

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory follicular lymphoma.

The FDA has accepted for review the resubmitted BLA for odronextamab in relapsed/refractor follicular lymphoma.

FDA approves Monjuvi combination for relapsed follicular lymphoma (FL): Monjuvi (tafasitamab-cxix) plus rituximab and lenalidomide was found to significantly improve progression-free survival in ...